Table 2. Predicted SARS-CoV-2 pharmacodynamics showing the daily fluoxetine dose and corresponding percent of the population (n=1,000) achieving a trough plasma concentration of 4.7 ng/ml (EC50-plasma) and 23.2 ng/ml (EC90-plasma), which leads to 60-times higher lungs based on the target EC50 (283.6 ng/ml [0.82 μM]) and EC90 (1390.1 ng/ml [4.02 μM]) concentrations, during a treatment period of 10-days.
| 20 mg/day | 30 mg/day | 40 mg/day | 50 mg/day | 60 mg/day | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Time point | %EC50 | %EC90 | %EC50 | %EC90 | %EC50 | %EC90 | %EC50 | %EC90 | %EC50 | %EC90 |
| Day 1 | 85.7 | 0.3 | 94.9 | 4.2 | 97 | 14.7 | 98.2 | 34 | 98.7 | 51.6 |
| Day 2 | 93 | 6.7 | 96.4 | 33.3 | 97.6 | 56.9 | 98.6 | 72.4 | 98.7 | 82.1 |
| Day 3 | 93.2 | 19.4 | 96.5 | 52.6 | 97.6 | 71.2 | 98.6 | 81.5 | 98.7 | 85.9 |
| Day 4 | 93.2 | 30.8 | 96.6 | 59.7 | 97.7 | 75.4 | 98.6 | 83 | 98.7 | 87.1 |
| Day 5 | 93.2 | 37.9 | 96.6 | 64.2 | 97.7 | 77.6 | 98.6 | 83.7 | 98.7 | 87.4 |
| Day 6 | 93.2 | 42.3 | 96.6 | 66.1 | 97.8 | 78.1 | 98.6 | 83.9 | 98.7 | 87.4 |
| Day 7 | 93.2 | 44.5 | 96.6 | 67.1 | 97.8 | 78.5 | 98.6 | 83.9 | 98.7 | 87.6 |
| Day 8 | 93.2 | 45.8 | 96.6 | 67.6 | 97.8 | 78.5 | 98.6 | 83.9 | 98.7 | 87.6 |
| Day 9 | 93.2 | 46.6 | 96.6 | 67.8 | 97.8 | 78.5 | 98.6 | 83.9 | 98.7 | 87.6 |
| Day 10 | 93.2 | 47 | 96.6 | 68 | 97.8 | 78.6 | 98.6 | 83.9 | 98.7 | 87.6 |